Real-life use of bone-targeting agents for bone metastases in France between 2009 and 2018: Results of the OPTIMOS study.

ABSTRACT:

Aim

To determine the use of bone-targeting agents (BTAs) in clinical practice in France and the occurrence of skeletal-related events (SREs) in cancer patients with bone metastases.

Methods

This study analysed data, recorded prospectively in a French National Health Insurance database, for patients who had a first diagnosis of bone metastases between 2009 and 2018.

Results

A total of 6,663 patients were analysed (mean age 69.7 ± 13.2 years, 53.2 % male) corresponding to 2,363 bone metastases only patients and 4,300 patients with SREs at inclusion. The most frequent primary cancers were breast (15.8 %), prostate (13.4 %), lung (12.6 %) and digestive cancer (10.6 %). Six-hundred and twenty-one patients (9.3 %) were treated with BTAs (52.7 % with denosumab). Median [IQR]

SUBMITTER: Confavreux CB 

PROVIDER: S-EPMC12811524 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature